Comprehensive Research Plan:

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly

Environmental Scan

October 1st, 2014
ODPRN Drug Class Review Proposal: Environmental Scan

Study Title: Antipsychotic Use in the Elderly

Objectives:
1. To summarize the pharmacy benefit programs for antipsychotics (with a focus on the atypicals) in Ontario, across Canada and in select international jurisdictions
2. To determine the impact of different drug reimbursement schemes for antipsychotics (e.g., restricted access) on patient access, quality of life and/or utilization and costs
3. To summarize the guidelines for management of antipsychotic use in the elderly, with a particular emphasis on dementia and related behaviours

Study Questions: In elderly patients:

1. How are antipsychotics (in particular atypical antipsychotics) currently being accessed in publicly funded programs across Canada as well as internationally?
2. What is the impact of different drug reimbursement schemes for atypical antipsychotics (e.g., restricted access) on patient access, quality of life and/or utilization and costs?
3. Does sex, gender or socioeconomic status play an important role in any of the analyses described?

Objective 1: Pharmacy Benefit Programs in Ontario, across Canada and internationally

Study Design:
Design: summary of available information available through the Internet; interviews with individuals at the government agencies responsible for the public drug plan
Data sources: Internet, direct contact with individuals

Study Population:
- Canada: provincial/territorial public plans
- England, Wales, Northern Ireland, Scotland: NICE (National Institute for Health and Care Excellence)
- Australia: Pharmaceutical Benefits Scheme
- United States: Medicare, Veterans Affairs
- New Zealand: PHARMAC (Pharmaceutical Management Agency)

Intervention:
- Atypical antipsychotics
  - aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
## Objective 2: Impact of different drug reimbursement schemes for atypical antipsychotics

**Study Design:**
- **Design:** Literature review
- **Data sources:** Medline, EMBASE, Cochrane Collection, Grey literature

**Study Population:**
- Atypical antipsychotics for the elderly (not for the diagnosis of schizophrenia, bipolar or other psychotic disorders)

**Intervention:**
- Various drug reimbursement schemes, including general benefits, step therapy, special authorization

**Outcome(s) of Interest:**
- Indirect/direct measurements of clinical outcomes, patient satisfaction, quality of life, utilization and/or costs

## Objective 3: Guidelines for use of antipsychotics in the elderly

**Study Design:**
- **Design:** Literature review
- **Data sources:** Medline, EMBASE, Cochrane Collection, Grey literature

**Study Population:**
- Atypical antipsychotics for the elderly (not for the diagnosis of schizophrenia, bipolar or other psychotic disorders)

**Intervention:**
- Guidelines/recommendations for the use of antipsychotics in the elderly

**Outcome(s) of Interest:**
- Published guidelines by various organizations: Canadian Consensus (2012), EFNS-ENS guidelines (2012)